Form 8-K · Current Report · Filed 2025-04-30
Johnson & Johnson Director Retirement and Annual Meeting Results
Johnson & Johnson announced that D. Adamczyk will retire from the Board of Directors effective May 31, 2025, for personal reasons. The 2025 Annual Meeting of Shareholders resulted in the election of all 11 Director nominees, approval of executive compensation, ratification of PricewaterhouseCoopers LLP as the independent auditor, and the rejection of proposals for voting on excessive golden parachutes and a human rights impact assessment.
- Filer
- Johnson & Johnson JNJ · NYSE
- Filed
- Accession
- 0000200406-25-000141
- CIK
- 0000200406
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Submission of Matters to a Vote of Security Holders
Financial Statements and Exhibits
Market reaction
Close before filing
$155.91
Next session
-0.9%
Since filing
+64.4%
Latest close
$256.35
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from JNJ reporting the same item, with the next session's move:
About Johnson & Johnson
Johnson & Johnson is a multinational corporation engaged in the research, development, production, and sale of a broad range of healthcare products. Primarily known for its pharmaceuticals, medical devices, and consumer health products, Johnson & Johnson has a significant presence in the global healthcare industry. It develops medications for a variety of fields such as immunology, oncology, neurology, infectious diseases, and vaccines. The company also produces a wide array of medical devices for surgery, orthopedics, and cardiovascular health. In addition to pharmaceuticals, Johnson & Johnson is renowned for its consumer health products, including baby care, skin and hair care, wound care, and over-the-counter pharmaceuticals, with well-recognized brands like Band-Aid, Tylenol, and Neutrogena. Operating globally, the corporation's extensive portfolio and commitment to healthcare innovation make it a pivotal player in the industry, ensuring it remains influential in addressing worldwide health challenges and advancing medical technology.
Never miss another JNJ filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.